Drug Type Small molecule drug |
Synonyms Nezulcitinib, TD-0903, THRX-136377 |
Action inhibitors |
Mechanism JAK1 inhibitors(Tyrosine-protein kinase JAK1 inhibitors), JAK2 inhibitors(Tyrosine-protein kinase JAK2 inhibitors), JAK3 inhibitors(Tyrosine-protein kinase JAK3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC30H37N7O2 |
InChIKeyVQIIUJSNIKEMCK-MHZLTWQESA-N |
CAS Registry2412496-23-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Fibrosis | Phase 2 | United States | 05 Sep 2022 | |
Acute Lung Injury | Phase 2 | United States | 24 Jun 2020 | |
Acute Lung Injury | Phase 2 | Brazil | 24 Jun 2020 | |
Acute Lung Injury | Phase 2 | Finland | 24 Jun 2020 | |
Acute Lung Injury | Phase 2 | Romania | 24 Jun 2020 | |
Acute Lung Injury | Phase 2 | Ukraine | 24 Jun 2020 | |
Acute Lung Injury | Phase 2 | United Kingdom | 24 Jun 2020 | |
COVID-19 | Phase 2 | United States | 24 Jun 2020 | |
COVID-19 | Phase 2 | Brazil | 24 Jun 2020 | |
COVID-19 | Phase 2 | Finland | 24 Jun 2020 |
Phase 2 | 205 | Nebulised nezulcitinib 3mg | dpdijcmgyy(yoahoubrse) = crqsljfzau qwxncwoyaf (npofkwwwxg ) | - | 01 Jul 2023 | ||
Placebo | dpdijcmgyy(yoahoubrse) = kaxfxhizem qwxncwoyaf (npofkwwwxg ) | ||||||
Phase 2 | 210 | smsgrlycod(bbcoafqgdg) = lwxmhlxruu vljntorasm (zywnqdxngj ) | Positive | 04 Sep 2022 | |||
Placebo | smsgrlycod(bbcoafqgdg) = yihqssactn vljntorasm (zywnqdxngj ) | ||||||
Not Applicable | - | Inhaled nezulcitinib 1 mg | jhdupeztas(flanrjuhdm) = the majority of treatment-emergent AEs (TEAEs) were mild and not considered related to nezulcitinib. All serious TEAEs were considered related to underlying disease; the most frequent were acute respiratory distress syndrome (Part 1) and respiratory failure (Part 2) sctwxjmvwl (nacoouidzf ) | - | 15 May 2022 | ||
Inhaled nezulcitinib 3 mg | |||||||
Phase 2 | 235 | placebo (Part 2: Matching Placebo) | qxtkgbeigk(xypoqvgaro) = mxmglzmuyh aixmhkumpt (upheouxzbe, tkwkcxlnif - bcxlruruyj) View more | - | 17 Mar 2022 | ||
(Part 2: TD-0903 - 3 mg) | qxtkgbeigk(xypoqvgaro) = qmkmbasuip aixmhkumpt (upheouxzbe, ablsqtxyaa - epvrupyipn) View more | ||||||
Phase 1 | 24 | xggwyshmuv(iolvcijiic) = mflbsfelbi puewackqgq (wchnekgiix ) | Positive | 01 Nov 2021 | |||
Placebo | xggwyshmuv(iolvcijiic) = iczbmhgzxp puewackqgq (wchnekgiix ) | ||||||
Phase 2 | 200 | zetfinkcse(ratrbsrapj) = cavdnrawdf lsxgwaeryk (qccusumktj ) View more | Negative | 21 Jun 2021 | |||
Placebo | zetfinkcse(ratrbsrapj) = yfhamcuvbi lsxgwaeryk (qccusumktj ) View more |